JPH025760B2 - - Google Patents

Info

Publication number
JPH025760B2
JPH025760B2 JP60071283A JP7128385A JPH025760B2 JP H025760 B2 JPH025760 B2 JP H025760B2 JP 60071283 A JP60071283 A JP 60071283A JP 7128385 A JP7128385 A JP 7128385A JP H025760 B2 JPH025760 B2 JP H025760B2
Authority
JP
Japan
Prior art keywords
residue
leu
ser
val
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60071283A
Other languages
English (en)
Japanese (ja)
Other versions
JPS60252496A (ja
Inventor
Buruusu Uooresu Robaato
Hirataka Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Chemical Industry Co Ltd
Original Assignee
Asahi Chemical Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Industry Co Ltd filed Critical Asahi Chemical Industry Co Ltd
Publication of JPS60252496A publication Critical patent/JPS60252496A/ja
Publication of JPH025760B2 publication Critical patent/JPH025760B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Image Analysis (AREA)
JP60071283A 1984-04-06 1985-04-05 新規なヒト生理活性ポリペプチド Granted JPS60252496A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/597,372 US4879226A (en) 1984-04-06 1984-04-06 Novel human physiologically active polypeptide
US597372 1984-04-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP1164061A Division JPH0272122A (ja) 1989-06-28 1989-06-28 ヒトｔｎｆを有効成分として含有する医薬組成物
JP16406089A Division JPH0242986A (ja) 1989-06-28 1989-06-28 新規なヒト生理活性ポリペプチドをコードするｄｎａ

Publications (2)

Publication Number Publication Date
JPS60252496A JPS60252496A (ja) 1985-12-13
JPH025760B2 true JPH025760B2 (instruction) 1990-02-05

Family

ID=24391235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60071283A Granted JPS60252496A (ja) 1984-04-06 1985-04-05 新規なヒト生理活性ポリペプチド

Country Status (39)

Country Link
US (1) US4879226A (instruction)
EP (2) EP0158286A3 (instruction)
JP (1) JPS60252496A (instruction)
KR (1) KR920007399B1 (instruction)
AR (1) AR240475A1 (instruction)
AU (2) AU595480B2 (instruction)
BE (1) BE902119A (instruction)
BG (1) BG43355A3 (instruction)
BR (1) BR8501624A (instruction)
CA (1) CA1341348C (instruction)
CH (2) CH672790A5 (instruction)
DD (1) DD251785A5 (instruction)
DK (1) DK151985A (instruction)
EG (1) EG17965A (instruction)
ES (1) ES8704976A1 (instruction)
FI (1) FI86992C (instruction)
FR (1) FR2564097B1 (instruction)
GB (1) GB2158829B (instruction)
GR (1) GR850836B (instruction)
HK (1) HK102192A (instruction)
HU (1) HUT37813A (instruction)
IE (1) IE58833B1 (instruction)
IL (1) IL74804A (instruction)
IN (1) IN163653B (instruction)
IT (1) IT1218469B (instruction)
JO (1) JO1365B1 (instruction)
LU (1) LU85835A1 (instruction)
MA (1) MA20402A1 (instruction)
MT (1) MTP963B (instruction)
MY (1) MY101887A (instruction)
NO (1) NO174473C (instruction)
NZ (2) NZ231317A (instruction)
OA (1) OA07983A (instruction)
PL (1) PL156392B1 (instruction)
PT (1) PT80239B (instruction)
RO (1) RO93650B (instruction)
SG (1) SG77892G (instruction)
YU (1) YU57885A (instruction)
ZA (1) ZA852563B (instruction)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
JP2584206B2 (ja) * 1984-08-17 1997-02-26 大日本製薬株式会社 ヒト癌壊死因子
DE19975063I2 (de) * 1984-03-06 2005-08-18 Dainippon Pharmaceutical Co DNS den menschlichen Tumornekrosisfaktor kodierendund das menschliche Tumornekronisfaktor-Polypepti d.
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
JPS60228297A (ja) * 1984-04-24 1985-11-13 株式会社　東京タツノ 給油装置
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US6686455B1 (en) * 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
GR851626B (instruction) * 1984-07-05 1985-11-26 Genentech Inc
DE3581730D1 (de) * 1984-10-15 1991-03-14 Cetus Corp Menschlicher tumornekrosisfaktor.
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
EP0313104A3 (en) * 1984-12-21 1989-07-12 Biogen, Inc. Purification, production and use of tumor necrosis factors
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5059530A (en) * 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
DD263234A5 (de) * 1986-07-31 1988-12-28 Genentech,Inc.,Us Verfahren zur herstellung von arzneimitteln zur behandlung oder vorbeugung von retroviralen infektionen
DE3716513A1 (de) * 1987-05-16 1988-11-24 Basf Ag Proteine mit tnf-wirkung
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
US5071834A (en) * 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
CA2003981C (en) * 1988-12-27 2000-06-13 Hiroshi Ishimaru Pharmaceutical compositions and use thereof in the treatment of psoriasis
US5342613A (en) * 1988-12-27 1994-08-30 Health Research Inc. Pharmaceutical compositions and use thereof in the treatment of psoriasis
ES2098261T3 (es) * 1989-02-21 1997-05-01 Univ Washington Formas modificadas de hormonas reproductoras.
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
EP0491878B1 (en) 1989-08-16 1997-02-19 Chiron Corporation Compositions for the inhibition of protein hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
ATE212672T1 (de) * 1989-10-24 2002-02-15 Chiron Corp System zur freisetzung von infektiösen proteinen
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
EP0916678A3 (en) 1993-06-03 1999-05-26 Therapeutic Antibodies Inc. Method of clotting blood
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
JPH10504441A (ja) 1994-03-07 1998-05-06 カイロン コーポレイション Ｔｎｆ形成阻害のための組成物およびその使用
CN1182368A (zh) 1995-03-16 1998-05-20 伊姆特克药物公司 来源于胆汁的治疗免疫系统紊乱的免疫调节组合物
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
FR2733421B1 (fr) * 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7662367B2 (en) * 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US20040198819A1 (en) * 2001-06-20 2004-10-07 Young Aiping H. Biological response modifier composition and uses thereof
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
AU2003290948A1 (en) * 2002-11-15 2004-06-15 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
ATE472556T1 (de) 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
EP2742127B1 (en) 2011-08-12 2019-10-09 Mello Biotechnology, Inc. Inducable expression from the eukaryotic pol-2 promoter in prokaryotes
US10196662B2 (en) 2012-08-10 2019-02-05 Mello Biotechnology, Inc. Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
WO2015057968A2 (en) 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
ES2962885T3 (es) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
CN116715767A (zh) 2016-05-13 2023-09-08 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
EP3538547B1 (en) 2016-11-09 2021-07-07 Philogen S.p.A. Immunoconjugates comprising il-2, anti-fibronectin antibody and mutant tnf-alpha

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
US4359415A (en) * 1981-06-03 1982-11-16 University Of Tennessee Research Corporation Isolation of an antineoplastic protein fraction and an antineoplastic peptide fraction from human urine
JPS5821621A (ja) * 1981-07-31 1983-02-08 Hayashibara Biochem Lab Inc ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
JPS6011890B2 (ja) * 1981-12-21 1985-03-28 株式会社林原生物化学研究所 ツモアネクロシスフアクタ−の製造方法
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
JPS57140725A (en) * 1981-12-28 1982-08-31 Dainippon Pharmaceut Co Ltd Physiologically active substance having carcinostatic action
JPS58141785A (ja) * 1982-02-16 1983-08-23 Nippon Shinyaku Co Ltd 抗腫瘍物質の製法
US4481137A (en) * 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
US4447355A (en) * 1982-04-07 1984-05-08 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
JPS591288A (ja) * 1982-06-29 1984-01-06 Sato :Kk 連続値札印字装置
WO1984001288A1 (en) * 1982-10-06 1984-04-12 Takeshi Makitsubo Process for extracting tumor necrosis factor from macrophage
JPS59169492A (ja) * 1983-03-15 1984-09-25 Asahi Chem Ind Co Ltd ヒト融合細胞からの生理活性物質の産生方法
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPS6019719A (ja) * 1983-07-15 1985-01-31 Asahi Chem Ind Co Ltd 抗腫瘍活性を有する蛋白質
JPS5943617Y2 (ja) * 1983-08-26 1984-12-25 株式会社潤工社 広い周波数帯域において均一な特性を有する伝送線路用導体
JPS60112718A (ja) * 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd 抗腫瘍作用を示す蛋白性物質及びその製造方法
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
DE19975063I2 (de) * 1984-03-06 2005-08-18 Dainippon Pharmaceutical Co DNS den menschlichen Tumornekrosisfaktor kodierendund das menschliche Tumornekronisfaktor-Polypepti d.
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
JPS60260522A (ja) * 1984-06-07 1985-12-23 Asahi Chem Ind Co Ltd 遺伝子組換体が生産する生理活性物質の安定化法
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法

Also Published As

Publication number Publication date
NO174473C (no) 1994-05-11
AU595480B2 (en) 1990-04-05
GB2158829A (en) 1985-11-20
ZA852563B (en) 1986-05-28
BG43355A3 (en) 1988-05-16
HK102192A (en) 1992-12-24
FI851336A0 (fi) 1985-04-03
FR2564097A1 (fr) 1985-11-15
IE850863L (en) 1985-10-06
RO93650B (ro) 1988-03-31
PL156392B1 (pl) 1992-03-31
IE58833B1 (en) 1993-11-17
RO93650A (ro) 1988-03-30
IL74804A0 (en) 1985-07-31
EP0158286A3 (en) 1987-05-13
JPS60252496A (ja) 1985-12-13
KR920007399B1 (ko) 1992-08-31
YU57885A (en) 1989-02-28
FI86992C (fi) 1992-11-10
MTP963B (en) 1985-11-25
GR850836B (instruction) 1985-06-26
IT1218469B (it) 1990-04-19
PT80239B (pt) 1988-02-17
FI86992B (fi) 1992-07-31
IN163653B (instruction) 1988-10-22
DK151985A (da) 1985-10-07
EP0158286A2 (en) 1985-10-16
PT80239A (en) 1985-05-01
US4879226A (en) 1989-11-07
AR240475A1 (es) 1990-04-30
JO1365B1 (en) 1986-11-30
DK151985D0 (da) 1985-04-03
BE902119A (fr) 1985-10-04
IL74804A (en) 1991-06-30
IT8520242A0 (it) 1985-04-05
AU4016289A (en) 1989-12-07
GB8508864D0 (en) 1985-05-09
NZ231317A (en) 1991-01-29
EG17965A (en) 1994-01-30
SG77892G (en) 1992-10-02
CH675423A5 (instruction) 1990-09-28
NO851400L (no) 1985-10-07
FR2564097B1 (fr) 1989-09-22
NO174473B (no) 1994-01-31
PL252807A1 (en) 1986-02-25
ES541920A0 (es) 1987-05-01
BR8501624A (pt) 1985-12-03
AU4088285A (en) 1985-10-10
KR850007273A (ko) 1985-12-02
MA20402A1 (fr) 1985-12-31
CA1341348C (en) 2002-03-19
EP0354592A1 (en) 1990-02-14
OA07983A (en) 1987-01-31
LU85835A1 (fr) 1985-12-16
CH672790A5 (instruction) 1989-12-29
MY101887A (en) 1992-02-15
ES8704976A1 (es) 1987-05-01
GB2158829B (en) 1992-04-22
HUT37813A (en) 1986-02-28
AU637054B2 (en) 1993-05-20
DD251785A5 (de) 1987-11-25
FI851336L (fi) 1985-10-07
NZ211666A (en) 1990-01-29

Similar Documents

Publication Publication Date Title
JPH025760B2 (instruction)
JP2557053B2 (ja) 腫瘍壊死因子の精製、製造および使用法
KR940000542B1 (ko) 재조합 dna 기술에 의해 제조된 생리적 활성물질의 정제방법
EP0357067B1 (en) Recombinant natural killer cell activator
JPH0695939B2 (ja) ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
KR930000187B1 (ko) Dna 재조합 기술에 의해 제조된 생리적 활성물질의 안정화 방법 및 상기 물질을 함유하는 안정화 수용액 또는 분말의 제조방법
JPH0157955B2 (instruction)
JP2548204B2 (ja) 新生理活性ポリペプチド
JP2002523100A (ja) 新規なヒトリゾチーム遺伝子、それによりコードされたポリペプチド、およびそれらの作製方法
JP2515975B2 (ja) 抗腫瘍作用を有するポリペプチド
JPS61291598A (ja) 魚類カルシトニン誘導体及びその製造方法
JPH0242986A (ja) 新規なヒト生理活性ポリペプチドをコードするｄｎａ
JPS61293924A (ja) 生理活性物質の受容タンパク
JPH01156999A (ja) ヒト癌壊死因子
JPH066066B2 (ja) 遺伝子組換体の産生する生理活性物質の熱処理法
JPS60166696A (ja) 新規生理活性ポリペプチドのｄνａ
JPH0272122A (ja) ヒトｔｎｆを有効成分として含有する医薬組成物
JPS60221092A (ja) 新規生理活性ポリペプチドのｄｎａ
JPH07102151B2 (ja) 新規なポリペプチドの製造法
JPS62135493A (ja) ガン壊死因子
JPH06172395A (ja) インターロイキン−１β誘導体及び医薬
JPS61293994A (ja) ラベル化された生理活性タンパク及びその製造方法

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term